PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31543464-3	2019	Asciminib, an allosteric inhibitor targeting the myristoyl-binding pocket of BCR-ABL1, is active against most single mutants but ineffective against all tested compound mutants.	S-tetradecanoyl-coenzyme A	49-58	BCR activator of RhoGEF and GTPase	Homo sapiens	77-85	
31826340-1	2019	BACKGROUND: Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors.	S-tetradecanoyl-coenzyme A	62-71	BCR activator of RhoGEF and GTPase	Homo sapiens	84-92